Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Parallel-Group, Adaptive Study Evaluating the Pharmacokinetics of a Single Oral Dose of Momelotinib in Subjects with Hepatic Impairment (HI) and Healthy Matched Control Subjects with Normal Hepatic Function

Next Previous
Search
Trial Profile

A Phase 1, Open-Label, Parallel-Group, Adaptive Study Evaluating the Pharmacokinetics of a Single Oral Dose of Momelotinib in Subjects with Hepatic Impairment (HI) and Healthy Matched Control Subjects with Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 28 Dec 2017 Results of this and other study (renal impairment, profile:270241), published in the Journal of Clinical Pharmacology.
  • 20 Apr 2016 New trial record
  • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top